CA2128142A1 - Combinaison pharmaceutique contenant un inhibiteur ras et un antagoniste d'endotheline pour le traitement des maladies cardiovasculaires - Google Patents

Combinaison pharmaceutique contenant un inhibiteur ras et un antagoniste d'endotheline pour le traitement des maladies cardiovasculaires

Info

Publication number
CA2128142A1
CA2128142A1 CA002128142A CA2128142A CA2128142A1 CA 2128142 A1 CA2128142 A1 CA 2128142A1 CA 002128142 A CA002128142 A CA 002128142A CA 2128142 A CA2128142 A CA 2128142A CA 2128142 A1 CA2128142 A1 CA 2128142A1
Authority
CA
Canada
Prior art keywords
treatment
cardiovascular disorders
endothelin antagonist
pharmaceutical combination
combination containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002128142A
Other languages
English (en)
Other versions
CA2128142C (fr
Inventor
Jean-Paul Clozel
Martine Clozel
Wolfgang Osterrieder (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2128142A1 publication Critical patent/CA2128142A1/fr
Application granted granted Critical
Publication of CA2128142C publication Critical patent/CA2128142C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002128142A 1993-07-15 1994-07-15 Combinaison pharmaceutique contenant un inhibiteur ras et un antagoniste d'endotheline pour le traitement des maladies cardiovasculaires Expired - Lifetime CA2128142C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH213193 1993-07-15
CH2131/93 1993-07-15

Publications (2)

Publication Number Publication Date
CA2128142A1 true CA2128142A1 (fr) 1995-01-16
CA2128142C CA2128142C (fr) 2007-03-06

Family

ID=4226611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002128142A Expired - Lifetime CA2128142C (fr) 1993-07-15 1994-07-15 Combinaison pharmaceutique contenant un inhibiteur ras et un antagoniste d'endotheline pour le traitement des maladies cardiovasculaires

Country Status (25)

Country Link
US (1) US5696116A (fr)
EP (1) EP0634175B1 (fr)
JP (1) JP2746537B2 (fr)
KR (1) KR100370181B1 (fr)
CN (1) CN1105573C (fr)
AT (1) ATE198551T1 (fr)
AU (1) AU683262B2 (fr)
BR (1) BR9402815A (fr)
CA (1) CA2128142C (fr)
CZ (1) CZ285413B6 (fr)
DE (1) DE59409631D1 (fr)
DK (1) DK0634175T3 (fr)
ES (1) ES2154277T3 (fr)
GR (1) GR3035702T3 (fr)
HU (1) HU221202B1 (fr)
IL (1) IL110272A (fr)
NO (1) NO312578B1 (fr)
NZ (1) NZ260969A (fr)
PL (1) PL176445B1 (fr)
PT (1) PT634175E (fr)
RU (1) RU2146522C1 (fr)
SA (1) SA94150155B1 (fr)
TW (1) TW287949B (fr)
UA (1) UA27870C2 (fr)
ZA (1) ZA944980B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
JP2001523218A (ja) 1996-02-20 2001-11-20 ブリストル―マイヤーズ・スクイブ・カンパニー ビフェニルイソキサゾール・スルホンアミドの製造法
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU750755B2 (en) * 1997-09-26 2002-07-25 Abbvie Deutschland Gmbh & Co Kg Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CN1234357C (zh) * 1998-07-10 2006-01-04 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
CN1838957A (zh) * 2003-08-22 2006-09-27 舍林股份公司 抑制趋化因子的哌嗪衍生物及其治疗心肌炎的用途
CN101312962A (zh) * 2005-12-06 2008-11-26 参天制药株式会社 角膜结膜病变的治疗剂
EP2091539A1 (fr) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Utilisation de l'ambrisentan associé avec un inhibiteur de rénine dans les troubles de l'hypertension
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
MA49664A (fr) 2017-02-27 2020-06-03 Idorsia Pharmaceuticals Ltd Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4470972A (en) * 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
DE3542794A1 (de) * 1985-12-04 1987-06-11 Bayer Ag Antihypertensives kombinationspraeparat
DE58905990D1 (de) * 1988-03-24 1993-12-02 Hoffmann La Roche Antihypertensives Kombinationspräparat.
JPH06505474A (ja) * 1991-01-31 1994-06-23 アボツト・ラボラトリーズ エンドセリン転換酵素阻害剤
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ATE156120T1 (de) * 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW216770B (fr) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists

Also Published As

Publication number Publication date
PL304292A1 (en) 1995-01-23
DE59409631D1 (de) 2001-02-15
DK0634175T3 (da) 2001-04-30
RU94026283A (ru) 1996-05-20
ATE198551T1 (de) 2001-01-15
UA27870C2 (uk) 2000-10-16
NO942650D0 (no) 1994-07-14
CZ285413B6 (cs) 1999-08-11
CA2128142C (fr) 2007-03-06
HU221202B1 (en) 2002-08-28
NZ260969A (en) 1996-01-26
CZ167794A3 (en) 1995-01-18
AU683262B2 (en) 1997-11-06
RU2146522C1 (ru) 2000-03-20
JPH0753408A (ja) 1995-02-28
KR960013371A (ko) 1996-05-22
CN1105573C (zh) 2003-04-16
AU6735794A (en) 1995-01-27
PL176445B1 (pl) 1999-05-31
IL110272A0 (en) 1994-10-21
BR9402815A (pt) 1995-04-04
ES2154277T3 (es) 2001-04-01
EP0634175A1 (fr) 1995-01-18
CN1107364A (zh) 1995-08-30
KR100370181B1 (ko) 2003-04-26
NO942650L (no) 1995-01-16
US5696116A (en) 1997-12-09
HU9402064D0 (en) 1994-09-28
NO312578B1 (no) 2002-06-03
EP0634175B1 (fr) 2001-01-10
GR3035702T3 (en) 2001-07-31
JP2746537B2 (ja) 1998-05-06
SA94150155B1 (ar) 2005-11-15
IL110272A (en) 1998-07-15
PT634175E (pt) 2001-06-29
HUT67331A (en) 1995-03-28
TW287949B (fr) 1996-10-11
ZA944980B (en) 1995-02-06

Similar Documents

Publication Publication Date Title
CA2128142A1 (fr) Combinaison pharmaceutique contenant un inhibiteur ras et un antagoniste d'endotheline pour le traitement des maladies cardiovasculaires
CA2186260A1 (fr) Composition contenant de la morphine, du polypyrrolidone et un polyalyleneoxyde
CA2218714A1 (fr) Forme galenique contenant de l'oxybutynine
CA2170647A1 (fr) Forme posologique sous forme de comprime composite (i)
ZA9610729B (en) Transdermal device for the delivery of flurbiprofen.
IL122783A (en) Cell adhesion inhibitors and pharmaceutical compositions containing the same
CA2163361A1 (fr) Derives de substitution de guanidines, agents therapeutiques
EP0668298A4 (fr) Copolymere maleique, son procede d'obtention et son utilisation.
EP1776954A3 (fr) Utilisation d'inhibiteurs du système rénine-angiotensine pour le traitement de l'accident cérébro-vasculaire
EP0840606A4 (fr)
AU7467294A (en) Tyrosine kinase inhibitor
CA2344407A1 (fr) Traitement de la manie et des troubles bipolaires
EP0862449A4 (fr) Inhibiteur de la chemokine
WO1993000094A3 (fr) Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
EP0726072A3 (fr) Composition pour traiter l'hypertension ou l'insuffisance cardiaque contenant un antagoniste d'angiotensine II et un inhibiteur d'endopeptidase
AU6090594A (en) Angiotensin ii inhibitors
AU4844496A (en) Novel biphenyl derivatives or salts thereof, and anti-inflammatory agents containing the same
FR2702804B1 (fr) Dispositif de serrage, notamment pour l'application de tôles ou profilés métalliques l'un contre l'autre.
GB9621974D0 (en) HIV integrase inhibitors
CA2055948A1 (fr) Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un antagoniste du calcium pour le traitement de la proteinurie
AU6659996A (en) An apparatus for packing spike plates or the like
AU6774694A (en) Taste-masking pharmaceutical compositions and methods for making the same
CA2169219A1 (fr) Derives de substitution de benzenesulfonylurees et de thio-urees; methode de preparation; utilisation pour l'obtention de preparations pharmaceutiques; preparations a base de ces derives
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
AP9901472A0 (en) Crystalline pharmaceutical product.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140715